Search research articles
Contact Us
Filters
Showing results (1-10 of 100) with videos related to
Page
of 10
Sort By:
Lancet (London, England)
|
June 19, 2022
Second-line CAR T cells for lymphomas
Alberto Mussetti, Anna Sureda
Blood
|
April 3, 2025
Prizloncabtagene autoleucel: a new CAR T cell for B-NHL
Alberto Mussetti, Anna Sureda
The Lancet. Oncology
|
July 6, 2023
γ-Secretase inhibitors plus anti-BCMA chimeric antigen receptor T cells
Alberto Mussetti, Anna Sureda
The Lancet. Haematology
|
January 21, 2020
What's behind chronic graft versus host disease incidence curves?
Alberto Mussetti, Anna Sureda
British Journal of Haematology
|
June 25, 2025
Allogeneic haematopoietic cell transplant should still be considered as a curative option for relapsed/refractory large B-cell lymphoma, including in the CAR T-cell era
Fernando Molina, Anna Sureda, Alberto Mussetti
Haematologica
|
September 25, 2025
Enhancing myeloablative fludarabine-busulfan conditioning with total marrow irradiation in high-risk myeloid disease
Fernando Molina, Alberto Mussetti, Anna Sureda
Hematology. American Society of Hematology. Education Program
|
December 9, 2023
CAR T-cell therapy in aggressive lymphomas-identifying prognostic and predictive markers
Alberto Mussetti, Nicole Fabbri, Anna Sureda
Current Opinion in Infectious Diseases
|
July 18, 2022
COVID19 in hematological patients and telemedicine: lessons learned across Europe and the US
Alberto Mussetti, Zinaida Peric, Cesar Figueroa
Leukemia & Lymphoma
|
August 14, 2012
Effective treatment of pomalidomide in central nervous system myelomatosis
Alberto Mussetti, Serena Dalto, Vittorio Montefusco
Journal of Clinical Medicine
|
October 29, 2020
Allogeneic Hematopoietic Transplantation for Multiple Myeloma in the New Drugs Era: A Platform to Cure
Alberto Mussetti, Maria Queralt Salas, Vittorio Montefusco
Page
of 10
Search research articles
Search
Showing results (1-10 of 100) with videos related to
Sort By:
Page
of 10
Lancet (London, England)
|
June 19, 2022
Second-line CAR T cells for lymphomas
Alberto Mussetti, Anna Sureda
Blood
|
April 3, 2025
Prizloncabtagene autoleucel: a new CAR T cell for B-NHL
Alberto Mussetti, Anna Sureda
The Lancet. Oncology
|
July 6, 2023
γ-Secretase inhibitors plus anti-BCMA chimeric antigen receptor T cells
Alberto Mussetti, Anna Sureda
The Lancet. Haematology
|
January 21, 2020
What's behind chronic graft versus host disease incidence curves?
Alberto Mussetti, Anna Sureda
British Journal of Haematology
|
June 25, 2025
Allogeneic haematopoietic cell transplant should still be considered as a curative option for relapsed/refractory large B-cell lymphoma, including in the CAR T-cell era
Fernando Molina, Anna Sureda, Alberto Mussetti
Haematologica
|
September 25, 2025
Enhancing myeloablative fludarabine-busulfan conditioning with total marrow irradiation in high-risk myeloid disease
Fernando Molina, Alberto Mussetti, Anna Sureda
Hematology. American Society of Hematology. Education Program
|
December 9, 2023
CAR T-cell therapy in aggressive lymphomas-identifying prognostic and predictive markers
Alberto Mussetti, Nicole Fabbri, Anna Sureda
Current Opinion in Infectious Diseases
|
July 18, 2022
COVID19 in hematological patients and telemedicine: lessons learned across Europe and the US
Alberto Mussetti, Zinaida Peric, Cesar Figueroa
Leukemia & Lymphoma
|
August 14, 2012
Effective treatment of pomalidomide in central nervous system myelomatosis
Alberto Mussetti, Serena Dalto, Vittorio Montefusco
Journal of Clinical Medicine
|
October 29, 2020
Allogeneic Hematopoietic Transplantation for Multiple Myeloma in the New Drugs Era: A Platform to Cure
Alberto Mussetti, Maria Queralt Salas, Vittorio Montefusco
Page
of 10